Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > iressa

Iressa (ZD1839 or gefitinib) : AstraZeneca : EGFR inhibitor

Latest News - Iressa Status
Clinical Research & FDA Approval
Iressa - Clinical Trials
Iressa Side Effects
EGFR Inhibitors & Mutations Research
egfr mutations & treatment response • egfr resistance & 2nd mutations • testing for egfr mutations

Latest News - Iressa Status

*** Patients and physicians can obtain the latest information about Iressa by calling the AstraZeneca Cancer Support Network at 1-866-992-9276 ***

FDA Statement on Iressa (US Food & Drug Administration)
Patient information regarding results of a large clinical trial of Iressa in patients with NSCLC that failed to show an overall survival advantage. Patients currently taking Iressa should consult with their doctors regarding continued use of Iressa. Alternative therapies are available. Certain subsets of patients may derive benefit from Iressa. The FDA's evaluation of the recent study results is ongoing. [12/04]

Iressa (National Cancer Institute)
Updated information on Iressa includes news of a recent trial that reporting that Iressa (gefitinib) was not associated with a significant survival improvement in the trial population of lung cancer patients. Includes links to recent FDA information on Iressa and to a letter from Astra-Zeneca to prescribing physicians discussing implications of the trial results. Discusses the FDA approval of Iressa in May 2003, explaining the clinical trials data (responses and side effects) that resulted in approval. Includes a link to the full prescribing information for Iressa. [1/05]



 

Clinical Research & FDA Approval

Iressa Approved for NSCLC: An Expert Interview with Alan B. Sandler, MD (Medscape)
Provides a brief summary of the basis for FDA approval of Iressa and offers a helpful Q & A with Dr. Alan Sandler to elucidate issues surrounding Iressa. Registration required for free access to Medscape. [5/03]

FDA Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets (The Oncologist)
by Martin H. Cohen et al.
v.8 The Oncologist (August 2003): 303-306
Summarizes the efficacy and safety results of clinical trials relevant to the approval of gefitinib (ZD1839; Iressa) as monotherapy treatment for patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel therapies. [8/03]

ZD1839 (Iressa): What's In It for the Patient? (The Oncologist)
by Ronald B. Natale and Susan L. Zaretsky
v.7, Suppl.4 The Oncologist (August 2002): 25-30
Provides an overview of ZD1839 (Iressa), the first of a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Discusses the results of two phase II trials that have shown that ZD1839 provides clinically significant symptom relief for many patients with extensively pretreated advanced NSCLC. Moreover, this improvement in disease-related symptoms correlated with improved survival and tumor response. ZD1839 also had an acceptable tolerability profile: most drug-related adverse events were mild and reversible. Some patients also experienced improved quality of life, particularly those with a partial response or stable disease. Concludes that ZD1839 offers a new treatment option providing meaningful symptom relief for many patients with NSCLC. [8/02]

Iressa & Treatment of Brain Metastases from NSCLC - Recent MEDLINE Abstracts (PubMed)



 

Iressa - Clinical Trials

Iressa - Clinical Trials (ClinicalTrials.gov)



 

Iressa - Side Effects

Iressa Treatment Q & A (CancerBACUP)
Provides basic information on Iressa: how it works, how it is given and possible side effects. [4/04]

Iressa & Interstitial Pneumonia - Recent MEDLINE Articles (PubMed)



 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor